News articles about Zoetis (NYSE:ZTS) have trended somewhat positive on Sunday, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zoetis earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.0951597145971 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
ZTS has been the topic of a number of research reports. Citigroup upgraded Zoetis from a “neutral” rating to a “buy” rating and set a $85.00 price target on the stock in a report on Thursday, January 4th. Craig Hallum restated a “buy” rating and issued a $85.00 price target (up previously from $77.00) on shares of Zoetis in a report on Tuesday, January 2nd. Cantor Fitzgerald set a $85.00 target price on Zoetis and gave the company a “buy” rating in a research note on Tuesday, January 2nd. Piper Jaffray reaffirmed a “buy” rating and issued a $86.00 target price on shares of Zoetis in a research note on Thursday, January 18th. Finally, Jefferies Group reaffirmed a “buy” rating and issued a $89.00 target price on shares of Zoetis in a research note on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $80.94.
Shares of Zoetis stock traded down $2.55 during trading hours on Friday, reaching $80.97. 2,752,329 shares of the company’s stock were exchanged, compared to its average volume of 2,550,576. Zoetis has a 52-week low of $52.36 and a 52-week high of $85.73. The firm has a market cap of $39,291.02, a PE ratio of 33.74, a P/E/G ratio of 1.81 and a beta of 0.96. The company has a quick ratio of 2.55, a current ratio of 3.85 and a debt-to-equity ratio of 2.77.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 15th. The company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter in the prior year, the company posted $0.47 EPS. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. equities research analysts anticipate that Zoetis will post 3.05 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be paid a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.62%. The ex-dividend date is Thursday, April 19th. Zoetis’s dividend payout ratio is presently 20.83%.
In other Zoetis news, insider Heidi C. Chen sold 37,453 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total transaction of $3,034,442.06. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Roxanne Lagano sold 35,663 shares of the stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total value of $2,889,416.26. Following the transaction, the executive vice president now directly owns 49,919 shares in the company, valued at approximately $4,044,437.38. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,952 shares of company stock worth $9,219,843. Corporate insiders own 0.31% of the company’s stock.
WARNING: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/zoetis-zts-earns-media-sentiment-score-of-0-17.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.